Peripartum cardiomyopathy in an intensive care unit setting

Abstract

Managing pregnant patients in the coronary care unit and the intensive care unit has been a challenge for many clinicians, as they do not encounter those special populations on a routine basis. Peripartum cardiomyopathy (PPCM) is an uncommon but potentially life-threatening condition that occurs during the last month of pregnancy or within five months of delivery. It is associated with left ventricular systolic dysfunction, leading to reduced ejection fraction and heart failure. Although the exact etiology remains unclear, potential contributing factors can include factors such as myocarditis, abnormal immune responses, genetic predispositions, and hormonal imbalances. The future implications of PPCM are wide. Besides physical illness, mental illness can also limit functionality and impose health challenges. Additionally, subsequent pregnancies carry an increased risk of recurrence, especially if cardiac function remains poor. Ongoing research into the molecular and genetic underpinnings of PPCM may pave the way for different targeted therapies and strategies focusing on prevention. Increasing awareness, early detection, and advances in treatment can significantly reduce morbidity and mortality associated with PPCM. Multidisciplinary care is crucial in optimizing outcomes for women affected and their families. This mini review aims to help appraise healthcare providers and clinicians in addressing and managing this challenging condition.

Keywords: Hemodynamic decompensation; Hemodynamic stabilization; Mechanical circulatory support; Bromocriptine therapy; Peripartum cardiomyopathy

Core Tip: Early recognition of peripartum cardiomyopathy is critical, as symptoms mimic heart failure and other acute conditions. Management includes guideline-directed heart failure therapy tailored to pregnancy/lactation, individualized hemodynamic and respiratory support, and mechanical circulatory support if needed. Bromocriptine may be considered in severe cases to improve left ventricular recovery, with concurrent anticoagulation due to thrombotic risk. Long-term care requires serial echocardiography, natriuretic peptide monitoring, and counseling on future pregnancy risks, as residual cardiac dysfunction may persist.